Found: 34
Select item for more details and to access through your institution.
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1419, doi. 10.1002/ajh.26686
- By:
- Publication type:
- Article
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 9, p. 869, doi. 10.1002/ajh.24423
- By:
- Publication type:
- Article
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 11, p. 1060, doi. 10.1002/ajh.24174
- By:
- Publication type:
- Article
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 3, p. 164, doi. 10.1002/ajh.21615
- By:
- Publication type:
- Article
Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.
- Published in:
- Scientific Reports, 2015, p. 14538, doi. 10.1038/srep14538
- By:
- Publication type:
- Article
Dynamics of chronic myeloid leukaemia.
- Published in:
- 2005
- By:
- Publication type:
- Letter
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 12, p. e2347950, doi. 10.1001/jamanetworkopen.2023.47950
- By:
- Publication type:
- Article
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
- Published in:
- Nature, 2012, v. 485, n. 7397, p. 260, doi. 10.1038/nature11016
- By:
- Publication type:
- Article
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
- Published in:
- Oncogene, 2003, v. 22, n. 47, p. 7389, doi. 10.1038/sj.onc.1206942
- By:
- Publication type:
- Article
Complex Genomic Rearrangements Involving ETV6 :: ABL1 Gene Fusion in an Individual with Myeloid Neoplasm.
- Published in:
- Genes, 2023, v. 14, n. 10, p. 1851, doi. 10.3390/genes14101851
- By:
- Publication type:
- Article
DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S299, doi. 10.1016/j.clml.2019.07.253
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S220, doi. 10.1016/j.clml.2018.07.090
- By:
- Publication type:
- Article
Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISION.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S14, doi. 10.1016/j.clml.2017.09.042
- By:
- Publication type:
- Article
Five-Year Efficacy and Safety of Dasatinib and Imatinib by Baseline Comorbidity and Age in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) from DASISION.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S312, doi. 10.1016/j.clml.2017.07.113
- By:
- Publication type:
- Article
5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S307, doi. 10.1016/j.clml.2017.07.105
- By:
- Publication type:
- Article
4-Year Results from the Pivotal Phase 2 PACE Trial: Efficacy and Safety in Heavily Pretreated Leukemia Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S56, doi. 10.1016/j.clml.2016.07.082
- By:
- Publication type:
- Article
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.
- Published in:
- 2022
- By:
- Publication type:
- journal article
The Molecular Medicine Investigation Unit: Linking Patient Care and Scientific Inquiry in Physician-Scientist Training.
- Published in:
- Journal of Graduate Medical Education, 2020, v. 12, n. 1, p. 92, doi. 10.4300/JGME-D-19-00507.1
- By:
- Publication type:
- Article
Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 5, p. 942, doi. 10.1111/bjh.18883
- By:
- Publication type:
- Article
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.
- Published in:
- British Journal of Haematology, 2013, v. 162, n. 4, p. 548, doi. 10.1111/bjh.12382
- By:
- Publication type:
- Article
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily.
- Published in:
- Cancer (0008543X), 2009, v. 115, n. 18, p. 4136, doi. 10.1002/cncr.24504
- By:
- Publication type:
- Article
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2019, v. 10, n. 5, p. 193
- By:
- Publication type:
- Article
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure—response analysis of a Phase III study.
- Published in:
- Clinical Pharmacology, 2013, v. 5, p. 85, doi. 10.2147/CPAA.S42796
- By:
- Publication type:
- Article
Getting personal with cancer.
- Published in:
- Nature Medicine, 2013, v. 19, n. 6, p. 665, doi. 10.1038/nm.3199
- By:
- Publication type:
- Article
Bench to bedside: BRCA: From therapeutic target to therapeutic shield.
- Published in:
- Nature Medicine, 2008, v. 14, n. 5, p. 495, doi. 10.1038/nm0508-495
- By:
- Publication type:
- Article
Front-Line TKI Therapy for Chronic-Phase CML: the Luxury of Choice.
- Published in:
- 2012
- By:
- Publication type:
- Opinion
Changing Therapy in TKI-Resistant Chronic Myeloid Leukemia.
- Published in:
- Clinical Advances in Hematology & Oncology, 2014, v. 12, p. 7
- By:
- Publication type:
- Article
Ponatinib: Targeting the T315/ Mutation in Chronic Myelogenous Leukemia.
- Published in:
- Clinical Advances in Hematology & Oncology, 2011, v. 9, n. 12, p. 925
- By:
- Publication type:
- Article
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Corrigendum: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
- Published in:
- Nature Chemical Biology, 2014, v. 10, n. 8, p. 692, doi. 10.1038/nchembio0814-692d
- By:
- Publication type:
- Article
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
- Published in:
- Nature Chemical Biology, 2014, v. 10, n. 4, p. 305, doi. 10.1038/nchembio.1471
- By:
- Publication type:
- Article